Jon Florholmen

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

Kristin Kaasen Jørgensen, Inge Christoffer Olsen, Guro Løvik Goll et al. · The Lancet · 2017 · 806 citations

Pharmacy, Internal Medicine, Pharmacotherapy +11

Tissue levels of tumor necrosis factor-alpha correlates with grade of inflammation in untreated ulcerative colitis

Trine Olsen, Rasmus Goll, Guanglin Cui et al. · Scandinavian Journal of Gastroenterology · 2007 · 155 citations

Veterinary Medicine, Immunology, Pathology +17

TH1 and TH17 interactions in untreated inflamed mucosa of inflammatory bowel disease, and their potential to mediate the inflammation

Trine Olsen, Renathe Rismo, Guanglin Cui et al. · Cytokine · 2011 · 135 citations

Life Sciences, Immunology, Pathology +16

Risk of malnutrition and health-related quality of life in community-living elderly men and women: The Tromsø study

Jan‐Magnus Kvamme, Jan Abel Olsen, Jon Florholmen et al. · Quality of Life Research · 2010 · 110 citations · Full text

Agriculture, Geriatric Medicine, Nutritional Sciences +17

Results of the 2nd part Scientific Workshop of the ECCO (II): Measures and markers of prediction to achieve, detect, and monitor intestinal healing in Inflammatory Bowel Disease

Marco Daperno, Fabiana Castiglione, Lissy de Ridder et al. · Journal of Crohn s and Colitis · 2011 · 103 citations · Full text

Medicine, Clinical Sciences, Radiology +17